⚕️ HealthLine

Health, Medicine, Wellness and healthcare developments

healthline AI

Hims & Hers to Stop Selling Compounded Obesity Pill Amid Regulatory Scrutiny and Other Health Controversies

Telehealth company Hims & Hers will cease sales of its compounded version of Novo Nordisk's obesity pill, Wegovy, following a request by the US Department of Health and Human Services (HHS) for the Justice Department to probe the company's practices. This development comes amidst a broader landscape of controversy in healthcare, including debates over gender-affirming care, concerns about the integrity of medical research, and scrutiny of pharmaceutical pricing.

Fulqrum AI • 3 min read • 5 sources •
Read Full Analysis

Latest HealthLine

13
Articles
AI
Synthesis

Explore More

⚕️ All Health & Wellness

More HealthLine Articles (12)

healthline AI

Biotech News Roundup: TrumpRx Launches, Roivant's Breakthrough, and More

In a week filled with significant developments in the biotech industry, President Trump launched TrumpRx, a platform aimed at lowering drug prices, while Roivant's immune drug showed promising results in treating a rare skin disease. Meanwhile, the industry saw a flurry of comings and goings, IPOs, and advancements in gene therapy.

Fulqrum AI
3 min 5 sources

Feb 6, 2026

Read Analysis
healthline AI

Healthcare in Flux: Evidence, Policy, and the Pursuit of Better Health Outcomes

As the healthcare landscape continues to evolve, concerns about evidence-based policy, effective treatments, and the role of technology in medicine have come to the forefront. From the push for multi-cancer detection tests to the debate over vaccine schedules and the safety of statins, healthcare professionals and policymakers are grappling with complex issues that impact patient care.

Fulqrum AI
3 min 5 sources

Feb 6, 2026

Read Analysis
healthline AI

Health Policy and Research Updates: A Mixed Bag for Advocates and Scientists

Recent developments in health policy and research have yielded a mix of positive and negative outcomes, with a federal appeals court upholding a ruling blocking NIH's cap on research overhead payments, while federal health officials slash recommended childhood vaccinations, and a cancer drug deal is inked after a biotech IPO.

Fulqrum AI
4 min 5 sources

Jan 5, 2026

Read Analysis
healthline AI

Global Health in 2026: Emerging Trends and Challenges in Biopharma, Public Health, and Disability Advocacy

As the world enters a new year, the healthcare landscape is poised to undergo significant changes. From advancements in biopharma to debates around disability advocacy, several key trends are emerging that will shape the future of global health. Experts weigh in on the pressing issues that will dominate the conversation in 2026.

Fulqrum AI
3 min 5 sources

Jan 5, 2026

Read Analysis
healthline AI

Healthcare in Flux: Emerging Trends and Challenges in 2026

The healthcare industry is bracing for significant changes in 2026, from the integration of AI technology to shifts in funding priorities. As hospitals navigate the complexities of adopting new medical technology, researchers are making breakthroughs in genetic research and cancer prevention. Meanwhile, the National Institutes of Health is reevaluating its grant priorities, sparking concerns about the future of diversity, equity, and inclusion initiatives.

Fulqrum AI
3 min 5 sources

Jan 2, 2026

Read Analysis
healthline AI

Health Care in Flux: Emerging Trends and Challenges in 2026

The health care industry is poised for significant changes in 2026, with emerging trends in AI, genetic research, and funding shifts. As hospitals navigate the complexities of new medical technologies, questions arise about who will pay for these innovations. Meanwhile, researchers uncover new genetic variants that could protect against certain blood cancers, and NIH funding priorities are being reevaluated.

Fulqrum AI
3 min 5 sources

Jan 2, 2026

Read Analysis
View All Health & Wellness